As we move closer to the end of this year, it is unfortunate to note that U.S. drug shortages are at an all-time high. Also unfortunate is that this is not a new issue. Drug shortages have been occurring in the United States for far too long.
We’ve all seen the headlines: 2023 is shaping up to be the worst drug shortage year on record. This reality is problematic for patients, providers and manufacturers. At Fresenius Kabi, our purpose is to help patients gain better access to the life-saving treatments they need – when and where they need them most.
Fresenius Kabi is doing More in America to keep its workforce engaged and working hard for healthcare providers and the patients they serve. “The only way we as a company can fulfill our mission of ‘caring for life’ is through our employees,” says VP of HR Administration, Deborah Browne.
To help improve safety and efficiency – and, in some cases, to discourage drug diversion – many hospitals in the U.S. are transitioning to ready-to-administer (RTA) drug presentations. That’s why Fresenius Kabi is doing More in America to expand the ready-to-administer options available to clinicians and caregivers – by offering prefilled, standard strength, single-patient delivery platforms in syringes and IV bags.
More Support in America: Setting a High Standard for the Medical Science Liaison (MSL) profession in America
Fresenius Kabi, a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, has long been recognized as an international leader in parenteral nutrition.